Advertisement
Screener

Indivior Pharmaceuticals, Inc. (INDV) Material Contracts

Indivior Pharmaceuticals, Inc. Material Contracts

Every material contract the company filed as Exhibit 10 (executive pay plans, credit agreements, supplier and indemnity agreements), newest first, with the filing's own description.

  • 2026-09-15: Form 8-K; Exhibit 10.1; Description Deed of Variation and Termination effective September 9, 2026 between Indivior UK Limited and Reckitt Benckiser Healthcare (UK) Limited..
  • 2026-02-26: Form 10-K; Exhibit 10.25; Description Employment Agreement dated as of December 6, 2021 by Indivior Inc. and Jeff Burris..
  • 2026-02-26: Form 10-K; Exhibit 10.24; Description Employment Agreement dated as of January 1, 2015 by Reckitt Benckiser Pharmaceuticals, Inc. and Christian Heidbreder..
  • 2026-02-26: Form 10-K; Exhibit 10.23; Description Employment Agreement dated as of June 2, 2025 by Indivior, Inc. and Patrick A. Barry..
FiledFormExhibitDescription
2026-09-158-K10.1Deed of Variation and Termination effective September 9, 2026 between Indivior UK Limited and Reckitt Benckiser Healthcare (UK) Limited.
2026-02-2610-K10.25Employment Agreement dated as of December 6, 2021 by Indivior Inc. and Jeff Burris.
2026-02-2610-K10.24Employment Agreement dated as of January 1, 2015 by Reckitt Benckiser Pharmaceuticals, Inc. and Christian Heidbreder.
2026-02-2610-K10.23Employment Agreement dated as of June 2, 2025 by Indivior, Inc. and Patrick A. Barry.
2026-01-268-K10.7Indivior Pharmaceuticals, Inc. Non-Employee Director Compensation Policy.
2026-01-268-K10.6.4Form of Performance Stock Unit Award Agreement under the Indivior Pharmaceuticals, Inc. 2026 Omnibus Equity Incentive Plan.
2026-01-268-K10.6.3Form of Restricted Stock Unit Award Agreement under the Indivior Pharmaceuticals, Inc. 2026 Omnibus Equity Incentive Plan.
2026-01-268-K10.6.2Form of Restricted Stock Unit Award Agreement (Non-Employee Directors) under the Indivior Pharmaceuticals, Inc. 2026 Omnibus Equity Incentive Plan.
2026-01-268-K10.6.1Indivior Pharmaceuticals, Inc. 2026 Omnibus Equity Incentive Plan
2026-01-268-K10.5Indivior Pharmaceuticals, Inc. Amended and Restated U.S. Employee Stock Purchase Plan.
2026-01-268-K10.4Amended and Restated Indivior U.K. Savings Related Share Option Plan.
2026-01-268-K10.3Omnibus Amendment to the Indivior 2024 Long-Term Incentive Plan, Indivior Long-Term Incentive Plan, Indivior Group Deferred Bonus Plan 2018 and Indivior U.K. Savings Related Share Option Plan.
2026-01-268-K10.2Form of Indemnification Agreement.
2026-01-268-K10.1Note Purchase Agreement, first made as of November 4, 2024, by and among by and among RBP Global Holdings Limited, Indivior Global Holdings Limited, Piper Sandler Finance LLC, as Administrative Agent and the lenders from time to time party thereto, as amended by that certain First Amendment to Note Purchase Agreement effective January 26, 2026.
2025-08-228-K10.2CONFIDENTIALITY, PROPRIETARY RIGHTS AND NON-COMPETITION AGREEMENT
2025-08-228-K10.1EMPLOYMENT AGREEMENT
2025-07-3110-Q10.3Form of Non-Executive Director Deed of Indemnity.
2025-07-3110-Q10.2Form of Non-Executive Director Letter of Appointment.
2025-03-048-K10.2Employment Agreement with Joe Ciaffoni made March 3, 2025.
2025-03-048-K10.1Amended and Restated Relationship Agreement made as of March 3, 2025 by and among Indivior PLC, Oaktree Value Opportunities Fund, L.P., Oaktree London Liquid Value Opportunities Fund (VOF), L.P., Oaktree Phoenix Investment Fund, L.P. and Boston Patriot Arlington ST LLC.
2025-03-0310-K10.242Amendment to Employment Agreement with Ryan Preblick made as of April 25, 2024.
2025-03-0310-K10.241Employment Agreement with Ryan Preblick made as of November 19, 2020.
2025-03-0310-K10.233Separation Agreement by and between Indivior, Inc. and Mark Crossley as of February 26, 2025.
2025-03-0310-K10.232Amendment to Employment Agreement with Mark Crossley made as of April 25, 2024.
2025-03-0310-K10.231Employment Agreement with Mark Crossley made as of June 29, 2020.
2025-03-0310-K10.122Amendment to the License Agreement between Indivior Inc., Indivior U.K. Limited, and Aegis Therapeutics, LLC made November 2020, 2024.
2025-03-0310-K10.25Form of Executive Confidentiality, Proprietary Rights and Non-Competition Agreement
2025-03-0310-K10.22Form of Director Employment Agreement
2025-03-0310-K10.20The Indivior PLC U.S. Employee Stock Purchase Plan.
2025-03-0310-K10.17Rules of the Indivior 2024 Long-Term Incentive Plan.
2025-03-0310-K10.14The Indivior Inc. Incentive Compensation Policy.
2025-03-0310-K10.13Relationship Agreement made as of December 16, 2024 by and among Indivior PLC, Oaktree Value Opportunities Fund, L.P., Oaktree London Liquid Value Opportunities Fund (VOF), L.P., Oaktree Phoenix Investment Fund, L.P. and Boston Patriot Arlington ST LLC.
2025-03-0310-K10.10Master Packaging and Supply Agreement effective as of October 1, 2023 by and between Sharp Packaging Services, LLC, Indivior Inc., and Indivior U.K. Limited.

Similar stocks

Stock NameCountryMarket CapPE Ratio
Viking Therapeutics, Inc. (VKTX)United States$4.287B-8.51
Tango Therapeutics, Inc. (TNGX)United States$4.154B-42.53
Edgewise Therapeutics, Inc. (EWTX)United States$4.470B-22.23
AbCellera Biologics Inc. (ABCL)$3.879B-14.59
ACADIA PHARMACEUTICALS INC (ACAD)United States$3.823B11.45
Xenon Pharmaceuticals Inc. (XENE)$3.684B-14.27
Veradermics, Inc (MANE)United States$4.839B
Organon & Co. (OGN)United States$3.603B17.03
IDEAYA Biosciences, Inc. (IDYA)United States$3.540B-20.52
Erasca, Inc. (ERAS)United States$5.073B-19.96